The prescription will be limited to those who smoke more than 10 cigarettes a day

The prescription will be limited to those who smoke more than 10 cigarettes a day.

27-12-2019EFE

The Ministry of Health has announced that Zytabac and Champix will be made available to smokers from January 1, but there are conditions attached.

The prescription will be limited to those who smoke more than 10 cigarettes a day, really want to quit smoking and have been part of a group or individual support program.

Smokers will be given a tobacco dependency test and are urged to undergo therapy whilst they’re being treated.

The drugs will cost around 195,500 euros and 40% will be paid by the Health Ministry, which is roughly 10.41 euros per month or 20.82 euros for 60 tablets.

"The prescription is restricted to doctors who define the IB-Salut because they will do it by container, prescribing one treatment per year for a maximum of twelve weeks,” said the Director General of Pharmacy, Nacho García.

García says that each study that has been done on the success of the drugs has given a different result.

"It depends on the motivation to quit and the support you receive,” he says. “Starting it up is very simple because in our community smoking programs are already available.”

In 2018, some 500 people attended workshops at their health centres to help them stop smoking, but by the end of the year, only 225 had people managed to quit.

Comments

The content of comment is the opinion of users and netizens and not of mallorcadailybulletin.com.

Comments contrary to laws, which are libellous, illegal or harmful to others are not permitted');

mallorcadailybulletin.com - reserves the right to remove any inappropriate comments.

Warning

Please remember that you are responsible for everything that you write and that data which are legally required can be made available to the relevant public authorities and courts; these data being name, email, IP of your computer as well as information accessible through the systems.

* Mandatory fields

Currently there are no comments.